1,228
Views
0
CrossRef citations to date
0
Altmetric
Microbiology (Medical)

Drug resistance patterns of Klebsiella pneumonia strains isolated from Shaoxing City, Zhejiang Province in 2019: a multi-centre retrospective study

, , , , , , , , , , , & ORCID Icon show all
Pages 875-883 | Received 05 Jan 2022, Accepted 08 Jun 2022, Published online: 11 Aug 2022

References

  • Adler A, Katz DE, Marchaim D. 2016. The continuing plague of extended-spectrum beta-lactamase-producing enterobacteriaceae infections. Infect Dis Clin North Am. 30(2):347–375. doi:10.1016/j.idc.2016.02.003.
  • Ballen V, Gabasa Y, Ratia C, Ortega R, Tejero M, Soto S. 2021. Antibiotic resistance and virulence profiles of Klebsiella pneumoniae strains isolated from different clinical sources. Front Cell Infect Microbiol. 11:738223. doi:10.3389/fcimb.2021.738223.
  • Caron F, Galperine T, Flateau C, Azria R, Bonacorsi S, Bruyere F, Cariou G, Clouqueur E, Cohen R, Doco-Lecompte T, et al. 2018. Practice guidelines for the management of adult community-acquired urinary tract infections. Med Mal Infect. 48(5):327–358. doi:10.1016/j.medmal.2018.03.005.
  • Centers for Disease Control and Prevention Facility. 2015. Guidance for control of carbapenem-resistant Enterobacteriaceae (CRE)—November 2015 Update CRE Toolkit.
  • Chang SL, Dela Cruz CS, Zhang D. 2021. Clinical epidemiology, risk factors, and control strategies of Klebsiella pneumoniae infection. Front Microbiol. 12:750662. doi:10.3389/fmicb.2021.750662.
  • Chen JW, Zeng Y, Zhang R, Cai JC. 2021. In vivo emergence of colistin and tigecycline resistance in carbapenem-resistant hypervirulent Klebsiella pneumoniae during antibiotics treatment. Front Microbiol. 12:702956. doi:10.3389/fmicb.2021.702956.
  • Chuang C, Su CF, Lin JC, Lu PL, Huang CT, Wang JT, Chuang YC, Siu LK, Fung CP, Lin YT. 2020. Does antimicrobial therapy affect mortality of patients with carbapenem-resistant Klebsiella pneumoniae bacteriuria? A nationwide multicenter study in Taiwan. Microorganisms. 8(12):2035. doi:10.3390/microorganisms8122035.
  • Clinical and Laboratory Standards Institute(CLSI). 2019. Performance standards for antimicrobial susceptibility testing, M100 29th ed. Wayne, PA: Clinical and Laboratory Standards Institute.
  • Di Tella D, Tamburro M, Guerrizio G, Fanelli I, Sammarco ML, Ripabelli G. 2019. Molecular epidemiological insights into colistin-resistant and carbapenemases-producing clinical Klebsiella pneumoniae isolates. Infect Drug Resist. 12:3783–3795. doi:10.2147/IDR.S226416.
  • Durante-Mangoni E, Andini R, Zampino R. 2019. Management of carbapenem-resistant enterobacteriaceae infections. Clin Microbiol Infect. 25(8):943–950. doi:10.1016/j.cmi.2019.04.013.
  • Effah CY, Sun TW, Liu SH, Wu YJ. 2020. Klebsiella pneumoniae: an increasing threat to public health. Ann Clin Microbiol Antimicrob. 19(1):1. doi:10.1186/s12941-019-0343-8.
  • Galani I, Karaiskos I, Angelidis E, Papoutsaki V, Galani L, Souli M, Antoniadou A, Giamarellou H. 2021. Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing Klebsiella pneumoniae of sequence type 39 during treatment. Eur J Clin Microbiol Infect Dis. 40(1):219–224. doi:10.1007/s10096-020-04000-9.
  • Hu FP, Guo Y, Yang Y, Zheng YG, Wu S, Jiang XF, Zhu DM, Wang F. 2019a. Resistance reported from China antimicrobial surveillance network (CHINET) in 2018. Eur J Clin Microbiol Infect Dis. 38(12):2275–2281. doi:10.1007/s10096-019-03673-1.
  • Hu Y, Liu C, Shen Z, Zhou H, Cao J, Chen S, Lv HY, Zhou MM, Wang Q, Sun L, et al. 2020. Prevalence, risk factors and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in patients from Zhejiang, China, 2008-2018. Emerg Microbes Infect. 9(1):1771–1779. doi:10.1080/22221751.2020.1799721.
  • Hu YJ, Ogyu A, Cowling BJ, Fukuda K, Pang HH. 2019b. Available evidence of antibiotic resistance from extended-spectrum beta-lactamase-producing enterobacteriaceae in paediatric patients in 20 countries: a systematic review and meta-analysis. Bull World Health Organ. 97(7):486–501B. doi:10.2471/BLT.18.225698.
  • Li X, Ding X, Shi P, Zhu Y, Huang Y, Li Q, Lu JM, Li ZP, Zhu L. 2019. Clinical features and antimicrobial susceptibility profiles of culture-proven neonatal sepsis in a tertiary children's hospital, 2013 to 2017. Medicine (Baltimore). 98(12): e14686. doi:10.1097/MD.0000000000014686.
  • Liu J, Gao Y, Wang X, Qian Z, Chen J, Huang Y, Meng ZJ, Lu XB, Deng GH, Liu F, et al. 2020. Culture-positive spontaneous ascitic infection in patients with acute decompensated cirrhosis: multidrug-resistant pathogens and antibiotic strategies. Yonsei Med J. 61(2):145–153. doi:10.3349/ymj.2020.61.2.145.
  • Maraolo AE, Corcione S, Grossi A, Signori A, Alicino C, Hussein K, Trecarichi EM, Viale P, Timsit JF, Veeraraghavan B, et al. 2021. The impact of carbapenem resistance on mortality in patients with Klebsiella pneumoniae bloodstream infection: an individual patient data meta-analysis of 1952 patients. Infect Dis Ther. 10(1):541–558. doi:10.1007/s40121-021-00408-8.
  • Ning GJ, Wang XX, Wu D, Yin ZD, Li YX, Wang HQ, Yang WZ. 2017. The etiology of community-acquired pneumonia among children under 5 years of age in mainland China, 2001-2015: a systematic review. Hum Vaccin Immunother. 13(11):2742–2750. doi:10.1080/21645515.2017.1371381.
  • San Millan A. 2018. Evolution of plasmid-mediated antibiotic resistance in the clinical context. Trends Microbiol. 26(12):978–985. doi:10.1016/j.tim.2018.06.007.
  • Schaeffer AJ, Nicolle LE. 2016. Clinical practice. Urinary tract infections in older men. N Engl J Med. 374(6):562–571. doi:10.1056/NEJMcp1503950.
  • Tang M, Kong X, Hao JC, Liu JB. 2020. Epidemiological characteristics and formation mechanisms of multidrug-resistant hypervirulent Klebsiella pneumoniae. Front Microbiol. 11:581543. doi:10.3389/fmicb.2020.581543.
  • Thomas AR, Candace MM. 2019. Hypervirulent Klebsiella pneumoniae. Clin Microbiol Rev. 32(3):e00001–e00019. doi:10.1128/CMR.00001-19.
  • World Health Organization (WHO). 2017. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. World Health Organization. 2017. Accessed on 1 Jan 2022. Available online: http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf.
  • Yang SS, Xu HF, Sun JD, Sun S. 2019. Shifting trends and age distribution of ESKAPEEc resistance in bloodstream infection, southwest China, 2012-2017. Antimicrob Resist Infect Control. 8:61. doi:10.1186/s13756-019-0499-1.
  • Zhang YW, Jin LY, Ouyang PW, Wang Q, Wang RB, Wang J, Gao H, Wang XJ, Wang H. 2020. Evolution of hypervirulence in carbapenem-resistant Klebsiella pneumoniae in China: a multicentre, molecular epidemiological analysis. J Antimicrob Chemother. 75(2):327–336. doi:10.1093/jac/dkz446.
  • Zhang YW, Wang Q, Yin YY, Chen HB, Jin LY, Gu B, Xie LY, Yang CX, Ma XB, Li HY, et al. 2018. Epidemiology of carbapenem-resistant enterobacteriaceae infections: report from the China CRE network. Antimicrob Agents Chemother. 62(2):e01882–e01817. doi:10.1128/AAC.01882-17.
  • Zhen XM, Stalsby Lundborg C, Sun XS, Gu SY, Dong HJ. 2020. Clinical and economic burden of carbapenem-resistant infection or colonization caused by Klebsiella pneumoniae, Pseudomonas aeruginosa. Acinetobacter Baumannii: A Multicenter Study in China. Antibiotics (Basel). 9(8):514. doi:10.3390/antibiotics9080514.